Novartis reports sustained efficacy of Rhapsido in chronic urticaria with benefits maintained through 52 weeks
Novartis reported 52-week Phase III results showing Rhapsido (remibrutinib) sustained efficacy in chronic inducible urticaria (CIndU). The drug improved symptoms in symptomatic dermographism, cold urticaria, and cholinergic urticaria. Response rates at Week 52 were 46.8%, 83.3%, and 58.2% respectively. Safety profile remained consistent with prior studies. Novartis aims to expand Rhapsido's availability.
How this was made
The 30-second read
Why it matters
The 52‑week data provide the most extensive efficacy evidence to date, supporting potential label expansion and future market uptake.
Market read
First comprehensive long‑term trial results for a novel urticaria therapy, likely to influence Novartis' stock and sector sentiment.
What to watch
Regulatory timelines and reimbursement negotiations could delay commercial impact despite strong data.
Background
Novartis' Rhapsido (remibrutinib) is an oral BTK inhibitor targeting chronic inducible urticaria, a niche but unmet therapeutic area.
Ticker impact
Novartis reported new 52‑week Phase III data for Rhapsido in chronic inducible urticaria, showing sustained efficacy and safety.
likely upward pressure as market prices in the favorable efficacy data.
First disclosure of comprehensive 52‑week outcomes; data are material for a large pharma and could influence upcoming regulatory filings.
Market effects
Strengthens the immunology/dermatology segment and may lift peer biotech stocks developing BTK inhibitors.
European and US markets could see modest gains in pharma indices.
Adds to global biotech pipeline confidence, potentially influencing investor sentiment worldwide.
Counterpoint
If the market has already priced in a positive outlook for Novartis' immunology franchise, the data may be already reflected.
Key entities
- CompanyNovartis
Swiss multinational pharmaceutical company developing Rhapsido.
- DrugRhapsido (remibrutinib)
Oral BTK inhibitor for chronic inducible urticaria.




